Document Detail


Ketanserin, hypertension, and chronic alcoholism: double-blind study in forty patients.
MedLine Citation:
PMID:  3068159     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In a randomized double-blind trial involving 40 alcoholic hypertensive patients, the antihypertensive activity of ketanserin, a serotonin antagonist with high affinity for S2 serotonergic receptors, was compared with a placebo. Patients in both groups were matched for age, body weight, blood pressure, alcoholic consumption, and length of alcoholism. The administration of ketanserin significantly reduced (p less than 0.001) mean supine blood pressure from 167/106 mmHg (22.3/14.1 kPa) at baseline to 145/87 mmHg (19.3/11.6 kPa) after 90 days of treatment versus a slight non-significant reduction with the placebo. No significant changes in heart rate, body weight, or laboratory parameters occurred. The incidence of side-effects was low in both groups. The results of this study suggest the possible role of serotonin in the pathogenesis of alcohol-related hypertension and the potential treatment of the disease using S2-receptor antagonists such as ketanserin.
Authors:
A de Lorenzo; M Ceccanti; G Assogna; M Romeo; G Cavaleri; M L Attilia
Related Documents :
24570839 - Aldosterone synthase inhibitors in hypertension: current status and future possibilities.
8638039 - Derivation of a target concentration of pb in soil based on elevation of adult blood pr...
12140349 - Caffeine affects cardiovascular and neuroendocrine activation at work and home.
8639709 - Hydrostatic pressure induces conformational and catalytic changes on two alcohol dehydr...
11787569 - Blood pressure and its biocultural correlates among the lepchas of sikkim, india: a mic...
23538309 - Hypertension and chronic kidney disease: controversies in pathogenesis and treatment.
1258959 - Increased intraocular pressure after third ventricle injections of prostaglandin e1 and...
25059759 - Circulatory responses to lower body negative pressure in young afghans and danes: impli...
8738899 - How does positive end-expiratory pressure decrease co2 elimination from the lung?
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  International journal of clinical pharmacology research     Volume:  8     ISSN:  0251-1649     ISO Abbreviation:  Int J Clin Pharmacol Res     Publication Date:  1988  
Date Detail:
Created Date:  1989-04-19     Completed Date:  1989-04-19     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8110183     Medline TA:  Int J Clin Pharmacol Res     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  321-5     Citation Subset:  IM    
Affiliation:
National Council of Research, Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Alcoholism / drug therapy*
Blood Pressure / drug effects
Clinical Trials as Topic
Double-Blind Method
Female
Humans
Hypertension / drug therapy*,  physiopathology
Ketanserin / administration & dosage,  adverse effects,  therapeutic use*
Male
Middle Aged
Random Allocation
Chemical
Reg. No./Substance:
74050-98-9/Ketanserin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Left atrial myxoma infected with Streptococcus viridans.
Next Document:  Effects of a synthetic prostanoid, rosaprostol, on the changes of gastric acidity and digestive diso...